P1.15. Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer by Prior Line of Systemic Therapy and Performance Status
Back to course
Pdf Summary
Asset Subtitle
Matteo Repetto, Memorial Sloan Kettering Cancer Center, United States
Meta Tag
Speaker Matteo Repetto, Memorial Sloan Kettering Cancer Center, United States
Topic Poster Listing
Keywords
larotrectinib
efficacy
safety
TRK fusion lung cancer
systemic therapy
TRK inhibitor
objective response rate
progression-free survival
overall survival
central nervous system metastases
Powered By